CSTL · Castle Biosciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.68M | - | $83.04M | $86.19M | $87.99M | - | $85.78M | $87.00M | $72.97M | - |
| Cost of Revenue | $20.53M | - | $18.70M | $17.63M | $16.38M | - | $15.61M | $14.52M | $13.89M | - |
| Gross Profit | $63.15M | - | $64.34M | $68.56M | $71.61M | - | $70.17M | $72.48M | $59.08M | - |
| R&D | $14.43M | - | $12.96M | $12.79M | $12.59M | - | $12.32M | $14.14M | $13.81M | - |
| SG&A | $64.90M | - | $55.91M | $58.06M | $58.62M | - | $50.50M | $51.09M | $48.49M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $3.93M | - | $1.54M | $1.45M | $29.76M | - | $1.27M | $1.10M | $3.34M | - |
| Operating Income | ($18.41M) | - | ($6.80M) | ($4.25M) | ($27.93M) | - | $5.08M | $5.01M | ($5.47M) | - |
| Interest Expense | $134.0K | - | $24.0K | $9.0K | $8.0K | - | $192.0K | $216.0K | $14.0K | - |
| Income Tax | $109.0K | - | $115.0K | ($4.67M) | ($423.0K) | - | $6.01M | ($1.03M) | $45.0K | - |
| Net Income | ($14.52M) | - | ($501.0K) | $4.52M | ($25.85M) | - | $2.27M | $8.92M | ($2.53M) | - |
| EPS - Basic | ($0.49) | - | ($0.02) | $0.16 | ($0.90) | - | $0.08 | $0.32 | ($0.09) | - |
| EPS - Diluted | ($0.49) | - | ($0.02) | $0.15 | ($0.90) | - | $0.08 | $0.31 | ($0.09) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63.76M | $116.73M | $85.56M | $82.23M | $89.69M | $119.71M | $94.96M | $85.57M | $82.95M | $98.84M |
| Accounts Receivable | $42.26M | $43.38M | $49.48M | $52.31M | $56.35M | $51.22M | $50.26M | $45.99M | $42.70M | $38.30M |
| Inventory | $10.46M | $10.25M | $8.65M | $8.37M | $6.85M | $8.13M | $6.57M | $8.01M | $7.64M | $7.94M |
| Accounts Payable | $15.04M | $18.71M | $12.21M | $13.18M | $8.50M | $6.90M | $6.81M | $9.54M | $9.32M | $10.27M |
| Current Assets | $328.90M | $361.10M | $357.57M | $348.67M | $349.39M | $360.15M | $344.77M | $320.40M | $295.78M | $295.63M |
| Total Assets | $547.80M | $578.56M | $562.79M | $544.73M | $501.71M | $531.24M | $514.57M | $487.31M | $458.51M | $453.34M |
| Current Liabilities | $48.76M | $68.68M | $55.31M | $50.89M | $37.27M | $49.39M | $44.30M | $39.45M | $31.96M | $47.67M |
| Long-term Debt | $8.40M | $9.64M | $10.05M | $8.10M | $8.92M | $9.74M | $10.02M | $10.01M | $0 | - |
| Total Liabilities | $86.39M | $107.68M | $95.74M | $89.35M | $61.41M | $75.40M | $73.51M | $63.42M | $56.05M | $62.07M |
| Stockholders' Equity | $461.42M | $470.87M | $467.05M | $455.38M | $440.31M | $455.83M | $441.06M | $423.89M | $402.46M | $391.27M |
| Retained Earnings | ($238.81M) | ($224.28M) | ($221.95M) | ($221.45M) | ($225.97M) | ($200.13M) | ($209.72M) | ($211.99M) | ($220.91M) | ($218.37M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($22.13M) | - | - | - | ($6.04M) | - | - | - | ($6.83M) | - |
| Investing Cash Flow | ($25.80M) | - | - | - | ($22.43M) | - | - | - | ($19.70M) | - |
| Financing Cash Flow | ($5.03M) | - | - | - | ($1.55M) | - | - | - | $10.64M | - |
| CapEx | $12.46M | - | - | - | $4.74M | - | - | - | $9.15M | - |
| Free Cash Flow | ($34.58M) | - | - | - | ($10.78M) | - | - | - | ($15.99M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 75.5% | - | 77.5% | 79.5% | 81.4% | - | 81.8% | 83.3% | 81.0% | - |
| Operating margin | -22.0% | - | -8.2% | -4.9% | -31.7% | - | 5.9% | 5.8% | -7.5% | - |
| EBITDA margin | -17.3% | - | -6.3% | -3.2% | 2.1% | - | 7.4% | 7.0% | -2.9% | - |
| Net margin | -17.4% | - | -0.6% | 5.2% | -29.4% | - | 2.6% | 10.3% | -3.5% | - |
| Free cash flow margin | -41.3% | - | - | - | -12.2% | - | - | - | -21.9% | - |
| FCF / Net income | 2.38 | - | - | - | 0.42 | - | - | - | 6.31 | - |
| R&D / Revenue | 17.2% | - | 15.6% | 14.8% | 14.3% | - | 14.4% | 16.2% | 18.9% | - |
| SG&A / Revenue | 77.6% | - | 67.3% | 67.4% | 66.6% | - | 58.9% | 58.7% | 66.5% | - |
| Effective tax rate | - | - | - | - | - | - | 72.6% | -13.1% | - | - |
| Return on assets | -2.7% | - | -0.1% | 0.8% | -5.2% | - | 0.4% | 1.8% | -0.6% | - |
| Return on equity | -3.1% | - | -0.1% | 1.0% | -5.9% | - | 0.5% | 2.1% | -0.6% | - |
| Return on invested capital | -3.1% | - | -1.1% | -0.7% | -4.9% | - | 0.6% | 1.2% | -1.1% | - |
| Liquidity | ||||||||||
| Current ratio | 6.75 | 5.26 | 6.47 | 6.85 | 9.37 | 7.29 | 7.78 | 8.12 | 9.25 | 6.20 |
| Quick ratio | 6.53 | 5.11 | 6.31 | 6.69 | 9.19 | 7.13 | 7.64 | 7.92 | 9.02 | 6.04 |
| Cash ratio | 1.31 | 1.70 | 1.55 | 1.62 | 2.41 | 2.42 | 2.14 | 2.17 | 2.60 | 2.07 |
| Leverage | ||||||||||
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | - |
| Debt / Assets | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | - |
| Debt / EBITDA | - | - | - | - | 4.86 | - | 1.58 | 1.64 | - | - |
| Interest coverage | -137.4x | - | -283.5x | -472.3x | -3491.0x | - | 26.5x | 23.2x | -390.8x | - |
| Equity multiplier | 1.19 | 1.23 | 1.20 | 1.20 | 1.14 | 1.17 | 1.17 | 1.15 | 1.14 | 1.16 |
| Liabilities / Assets | 0.16 | 0.19 | 0.17 | 0.16 | 0.12 | 0.14 | 0.14 | 0.13 | 0.12 | 0.14 |
| Efficiency | ||||||||||
| Asset turnover | 0.15 | - | 0.15 | 0.16 | 0.18 | - | 0.17 | 0.18 | 0.16 | - |
| Inventory turnover | 1.96 | - | 2.16 | 2.11 | 2.39 | - | 2.38 | 1.81 | 1.82 | - |
| Days sales outstanding | 184d | - | 217d | 222d | 234d | - | 214d | 193d | 214d | - |
| Days inventory outstanding | 186d | - | 169d | 173d | 153d | - | 154d | 201d | 201d | - |
| Days payable outstanding | 267d | - | 238d | 273d | 189d | - | 159d | 240d | 245d | - |
| Cash conversion cycle | 103d | - | 148d | 122d | 197d | - | 208d | 155d | 170d | - |
| Valuation | ||||||||||
| P / E | - | - | - | 136.1x | - | - | 356.5x | 70.2x | - | - |
| P / B | 1.6x | - | 1.4x | 1.3x | 1.3x | - | 1.9x | 1.5x | 1.5x | - |
| P / S | 8.8x | - | 8.0x | 7.0x | 6.5x | - | 9.8x | 7.2x | 8.3x | - |
| EV / EBITDA | - | - | - | - | 268.0x | - | 118.7x | 90.0x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -4.9% | - | -3.2% | -0.9% | 20.6% | - | 39.5% | 73.5% | 73.6% | - |
| Revenue CAGR (3y) | 25.8% | - | 30.9% | 35.2% | 48.5% | - | 54.0% | 56.4% | 47.3% | - |
| Revenue CAGR (5y) | 29.7% | - | 40.4% | 46.6% | 38.3% | - | 87.4% | 52.0% | - | - |
| Gross profit growth (YoY) | -11.8% | - | -8.3% | -5.4% | 21.2% | - | 39.9% | 85.5% | 85.5% | - |
| Operating income growth (YoY) | 34.1% | - | - | - | -410.5% | - | - | - | 82.6% | - |
| Net income growth (YoY) | 43.8% | - | - | -49.3% | -920.0% | - | - | - | 91.3% | - |
| EPS growth (YoY) | 45.6% | - | - | -51.6% | -900.0% | - | - | - | 91.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -220.9% | - | - | - | 32.6% | - | - | - | 44.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 4.8% | 3.3% | 5.9% | 7.4% | 9.4% | 16.5% | 14.3% | 11.9% | 4.5% | -2.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$344.23M totalReportable Segment$344.23M · 100.0%
Product / service
$344.23M totalDermatologic$216.37M · 62.9%
Non Dermatologic$127.86M · 37.1%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing CASTLE BIOSCIENCES INC against the 5 most active filers in the same SIC group.